Kelly Gaudian

Papers

Total Citations

H-Index

About

Kelly Gaudian is a radiation oncologist whose research focuses on optimizing treatment outcomes for prostate cancer patients, particularly through the study of radiation-related toxicities. Her key contributions center on understanding the interplay between radiation dose, treatment volume, and immune system effects. In her notable 2024 work, Gaudian investigated chronic lymphopenia following prostate stereotactic body radiation therapy (SBRT), with or without supplemental pelvic irradiation. This study highlighted how hypofractionated regimens may influence immune cell depletion, a critical factor in both treatment tolerance and long-term cancer control. While still early in her career, Gaudian’s work addresses a growing clinical concern: balancing the benefits of aggressive radiation with the risks of immunosuppression. Her research has practical implications for refining treatment planning, particularly in selecting patients who may benefit from pelvic nodal irradiation without compromising their immune function. As the field moves toward more personalized radiotherapy, Gaudian’s contributions help bridge the gap between dosimetric precision and biological outcomes, offering valuable insights for clinicians aiming to minimize toxicity while maintaining efficacy.